Amneal Pharmaceuticals (AMRX) EBITDA (2017 - 2026)

Amneal Pharmaceuticals has reported EBITDA for 10 years, with the latest figure at $129.8 million in Q2 2026.

• On a quarterly basis, EBITDA rose 16.52% year-over-year to $129.8 million in Q2 2026; TTM through Jun 2026 was $453.9 million, a 20.62% increase from a year earlier, with the FY2025 full-year figure at $394.1 million, up 58.06% from the prior year.
• EBITDA was $129.8 million for Q2 2026 at Amneal Pharmaceuticals, down from $141.8 million in the prior quarter.
• The five-year high for EBITDA was $141.8 million in Q1 2026, with the low at -$198.6 million in Q2 2022.
• Average EBITDA over 5 years is $56.9 million, with a median of $75.7 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: EBITDA sank 395.92% in 2022, then soared 1033.81% in 2025.
• Over 5 years, EBITDA stood at $36.0 million in 2022, then slumped by 60.61% to $14.2 million in 2023, then surged by 434.02% to $75.8 million in 2024, then surged by 47.81% to $112.0 million in 2025, then increased by 15.83% to $129.8 million in 2026.
• The last three EBITDA figures came in at $129.8 million (Q2 2026), $141.8 million (Q1 2026), and $112.0 million (Q4 2025), per Business Quant data.